Olatec Therapeutics

Dapansutrile: a new hope for #Parkinson’s? An exciting phase 2 clinical trial of dapansutrile (DAPA-PD), an anti-inflammatory drug, to determine whether it has the potential to slow the progression of Parkinson’s. We are fully committed to this groundbreaking collaboration among, Cure Parkinson's and University of Cambridge to find a cure for PD, in which this trial could bring us closer to achieving this. https://lnkd.in/eKAMuKR6 Dapansutrile was prioritised by the International Linked Clinical Trials (iLCT) programme in 2022, an initiative created and operated by Cure Parkinson’s and Van Andel Institute in an effort to speed up the search for disease-modifying  treatments for Parkinson’s. Dapansutrile is a novel molecule owned by Olatec Therapeutics Inc, which focuses on developing oral inflammation-targeting therapeutics. The DAPA-PD trial is funded by Cure Parkinson’s and Van Andel Institute and is a collaboration between the University of Cambridge and Olatec.

Olatec has been invited to present a scientific poster on dapansutrile, one of the most clinically advanced #NLRP3 inhibitors, at the American College of Rheumatology #ACR24 conference, in Washington, DC. This premier event for #rheumatology professionals will showcase the latest advancements and research in the field. #Dapansutrile (OLT1177®), a highly specific #NLRP3inhibitor, controls #inflammation by selectively targeting the #inflammasome without broadly impacting other immune pathways. This specificity reduces off-target effects, potentially offering a safer therapeutic option across multiple diseases. Olatec’s lead clinical trial in #acutegoutflare, PODAGRA-II (NCT05658575), a Phase 2/3 study, is ongoing. Positive results from this study could transform acute gout flare treatment, offering safer and more effective inflammation management through NLRP3 inhibition. See abstract (0934) here: https://lnkd.in/ejhQmZjZ For those attending the conference, Isak Tengesdal will be presenting tomorrow, Sunday, November 17, from 10:30 AM to 12:30 PM. For a copy of the poster, please contact us at inquiries@olatec.com.

Olatec is at the American Heart Association Scientific Sessions 2024 #AHA24 in Chicago, sharing a scientific poster on our ongoing #Type2Diabetes (T2DM) clinical trial, DAPAN-DIA (NCT06047262). This event provides a forum for breakthroughs in #cardiometabolic science and medicine, breakthroughs that have the potential to transform therapy practices for cardiometabolic conditions, #obesity, and related comorbidities. Our research focuses on an urgent unmet need for T2DM patients at risk for cardiometabolic and other complications. In our completed study in #heartfailure, patients showed improvements in heart function (LVEF) and glycemia (fasting glucose) with dapansutrile (OLT1177®) in T2DM.  Olatec’s ongoing clinical trial in T2DM patients will provide critical data on a new, clinically relevant aspect of T2DM care.  We believe that #dapansutrile (OLT1177®) has the potential to become a new therapeutic option for T2D patient that addresses both inflammation and cardiometabolic health. Join us to view our poster, presented by Antonio Abbate, on Saturday, November 16, from 2:00–3:00 PM in the Science and Technology Hall, South Building, Level 3. For a copy of the poster, please contact us at inquiries@olatec.com. https://lnkd.in/eai-zDWU

Isak Tengesdal was selected to present a poster EMBO on the need for new assays to be able to reliably assess #NLRP3inhibitors outside of #sulfonylureas chemotypes. For example, a new assay called NLRP3 NanoBRET® target engagement assay, does not adequately account for the unique molecular and binding properties of these NLRP3 inhibitors, like #dapansutrile, a #sulfonylnitrile, which has shown a promising safety profile for chronic use.  In their recent Frontiers paper, Tengesdal et al. (2024) highlight the crucial limitations of the NLRP3 NanoBRET® assay in evaluating inhibitors with non-sulfonylurea chemotypes like dapansutrile. Improved methods are essential for accurate screening. #EMBOinflammasomes24 https://lnkd.in/eYwtrCCk https://lnkd.in/eGKQUFx7

Olatec has been invited to present a scientific poster on dapansutrile, an #NLRP3inhibitor in clinical development in multiple diseases driven by inflammation at #EMBOinflammasomes24. The EMBO Workshop is bringing researchers together to advance inflammasome biology on September 24-27 in Germany. https://lnkd.in/eGKQUFx7

Olatec was selected to present BioCentury Inc Grand Rounds event September 9-11.  We invite you to join us and hear about the clinical status of dapansutrile, our specific NLRP3 inhibitor #NLRP3inhibitor #dapansutrilein #gout, #cardiometabolic and #neuroinflammatory diseases. 

A ground breaking clinical study with dapansutrile, and the largest clinical trial to investigate an NLRP3 inhibitor in patients with type 2 diabetes, obesity and low grade inflammation, many of whom will be on GLP-1 therapy.

The first patient with #type2diabetes and diabetes-related complications has been enrolled in a #Phase2 randomized #clinicaltrial of approximately 300 patients with elevated blood glucose, #systemicinflammation and at risk for complications of #diabetes, called DAPAN-DIA, with Olatec’s #NLRP3inhibitor, #dapansutrile. DAPAN-DIA represents the first T2D clinical trial of any selective NLRP3 inhibitor in the emerging class that will also assess cardiometabolic and other risk factors beyond anti-hyperglycemic effects including weight lowering efficacy in combination with GLP-1 therapy The study is being conducted as an investigator-sponsored study under Principal Investigator @Marc Donath MD at the University Hospital of Basel in Switzerland, a long-time Olatec collaborator and advisor as well as a leading researcher-clinician in immuno-metabolism. https://lnkd.in/eZ-RuyNr

Olatec’s CMO Mustafa A. Noor, MD, FACP & team will be presenting BIO International Convention #BIO2024 event on June 4 at 3:45p in Theater 3 to discuss Olatec’s clinical development of its #NLRP3inhibitor, #dapansutrile, including data to-date and near-term milestones. https://lnkd.in/ePWpQpSF

Olatec has been selected to present BIO International Convention #BIO2024 event on June 4 at 3:45p in Theater 3.  Please join our CMO, Mustafa A. Noor, MD, FACP who will discuss the clinical status and data on our #NLRP3inhibitor #dapansutrile in #gout, #cardiometabolic and #neuroinflammatory diseases. https://lnkd.in/ePWpQpSF